Personalised Cancer Medicine Flashcards 2022

Indications determined by the organ of origin



Currently not recommended
  • BRAF
  • KIT*
  • NRAS
  • GNAQ/GNA11
  • PTEN
  • MITF
  • CDKN2A
  • MHC-II
  • Tumor mutational burden
* in mucosal or acral melanoma or melanoma associated with sunlight
The Standard category is based on current treatment indications with approved funding by the Spanish National Health System.
The Recommended category is based on currentrecommendations by EMEA and FDA.


1. Martín-Algarra S, Fernández-Figueras MT, López-Martín JA, at al; Spanish Society of Pathology; Spanish Society of Medical Oncology. Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2014 Apr;16(4):362-73. doi: 10.1007/s12094-013-1090-5.

2. Scherrer E, Rau R, Lorenzi M, Shui I, Townson S, Larkin J. Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma. Future Oncol. 2021 Mar 30. doi: 10.2217/fon-2021-0154.

3. Mao L, Dai J, Cao Y, et al. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. Eur J Cancer. 2021 Mar 23;148:297-306. doi: 10.1016/j.ejca.2021.02.021.